NCT02145182 - Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study) | Biotech Hunter

Enrollment

288

Participants

Timeline

Start Date

August 21, 2014

Primary Completion Date

November 22, 2016

Study Completion Date

November 22, 2016

Conditions

Delayed Graft Function

Interventions

DRUG

Eculizumab

Eculizumab is a complement component 5 inhibitor.

DRUG

Placebo

0.9% sodium chloride

Trial Locations (78)

3168

Clayton

10032

New York

10065

New York

10126

Torino

10467

The Bronx

13353

Berlin

14000

Prague

20007

Washington D.C.

20162

Milan

20246

Hamburg

21287

Baltimore

22903

Charlottesville

23298

Richmond

24105

Kiel

25123

Brescia

27157

Winston-Salem

27599

Chapel Hill

28041

Madrid

29425

Charleston

30625

Hanover

30912

Augusta

31059

Toulouse

33076

Bordeaux

33606

Tampa

34346

Hannoversch Münden

35128

Padua

35294

Birmingham

37044

Tours

37126

Verona

39008

Santander

40536

Lexington

41013

Seville

44093

Nantes

45147

Essen

46017

Valencia

46026

Valencia

48109

Ann Arbor

48202

Detroit

50009

Zaragoza

55455

Minneapolis

60612

Chicago

63110

St Louis

67091

Strasbourg

69003

Lyon

70121

New Orleans

70124

Bari

75010

Paris

75743

Paris

76104

Fort Worth

77030

Houston

80045

Aurora

85054

Phoenix

90024

Los Angeles

91054

Erlangen

92150

Suresnes

94010

Créteil

94115

San Francisco

94143

San Francisco

94270

Le Kremlin-Bicêtre

94304

Palo Alto

98195

Seattle

06520

New Haven

02215

Boston

07039

Livingston

Unknown

Camperdown

Westmead

Adelaide

Vancouver

Halifax

Toronto

Montreal

05403-000

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo

01307

Dresden

08916

Badalona

08003

Barcelona

08035

Barcelona

08036

Barcelona

08907

Barcelona